600% Kurspotential YM Biosciences 911799
Seite 3 von 28 Neuester Beitrag: 19.02.13 20:54 | ||||
Eröffnet am: | 14.03.06 11:16 | von: qwertz | Anzahl Beiträge: | 694 |
Neuester Beitrag: | 19.02.13 20:54 | von: der Eibsche | Leser gesamt: | 132.694 |
Forum: | Hot-Stocks | Leser heute: | 16 | |
Bewertet mit: | ||||
Seite: < 1 | 2 | | 4 | 5 | 6 | 7 | 8 | 9 | ... 28 > |
Erstmal muss man sich ein gutes Spekulationskapital erwirtschaften, wenn man dann mal genügend Geld hat, kann man dann richtig dicke Dinger landen ;-)
am Anfang vll. 2000€ * 2,5 = 5000€ -> wenn man genügend hat 20.000€ x 2,5 = :-)
Ich würd die Meldung als "normal" werten mit nem "pos. Touch"
einfach Geduld haben
ich bin grad beim Aufbaun eines vernünftigen Spekulationskapitals ;-)
greetz
bei guten News hab ich aber auch vor länger zu halten ;-)
The trial is a single arm study in which 40 children with inoperable pontine glioma will be treated with radiation concomitant with nimotuzumab. The primary clinical endpoints in the trial will be progression-free survival with median survival as secondary endpoint. Clinical sites will be located in Germany, Italy, Belarus and Russia and it is anticipated that recruitment could be complete within approximately 12 months after the start of patient enrolment. Based on historical data reporting progression-free survival and median survival for this form of cancer of approximately 5.5 months and 8.5 months respectively, Oncoscience expects the trial should be completed in the first half of 2007.
YM BioSciences has previously announced that it and its majority owned subsidiary, CIMYM Inc., propose to file for authorization to conduct a trial in a similar patient population in North America. In addition YM is undertaking the clinical development of nimotuzumab in Non-Small Cell Lung Cancer. YM’s licensor, CIMAB SA and its parent, the Center for Molecular Immunology, are conducting trials with nimotuzumab in glioma, breast, esophageal, uterine cervix, prostate and head and neck cancer.
About Oncoscience AG
Oncoscience AG is a private biotech company based in Germany and is focused in Oncology (nimotuzumab), Organ Transplantation (Lifor) and tumor tissue banking including research in Genomics/Proteomics.
About YM BioSciences
YM BioSciences Inc. is a cancer product development company. Its lead drug, tesmilifene, is a small molecule chemopotentiator currently undergoing a 700-patient pivotal Phase III trial in metastatic and recurrent breast cancer. Published results from tesmilifene’s first Phase III trial in the same indication demonstrated a substantial increase in survival for women treated with the combination of tesmilifene and chemotherapy compared to chemotherapy alone, demonstrating that tesmilifene significantly enhanced the therapeutic effect of chemotherapy.
In addition to tesmilifene and nimotuzumab, the Company is also developing an anti-GnRH anti-cancer vaccine, Norelin™, for which Phase II data have been released. YM’s subsidiary DELEX Therapeutics Inc. is developing AeroLEF™, a unique inhalation delivered formulation of the established drug, fentanyl, to treat acute pain including cancer pain. This product has completed a Phase IIa trial with positive results and a randomized Phase IIb pain trial is ongoing. The Company also has a broad portfolio of preclinical compounds shown to act as chemopotentiators while protecting normal cells.
Na dann erklärt sich das auch evtl. warum die heute wieder so gut läuft! :-)
Ich schua im Netzt beim Aktionär, ob man da was findet.
bei der Aktie YM...brauch man weng Geduld Kursziel ~12€ 1Jahr+
-------------------------------------------------
Meine Zuversicht? Ich pers. finde das Unternehmen solide, die haben gute Projekte am laufen, die Zahlen passen auch soweit, und die Tochtergesellschaft (wo se sich u.a. beteiligt haben ist auch ok)
also alles in allem bin ich schon von dem Wert überzeugt, bzw. bin optimisstisch
greetz
In einem früheren Bericht (Quelle ist mir entgangen) wurde auch schon von Parkettkursen in NY von KZ bis 36,- US Dollar gesprochen.-Ach,träumen kann so schön sein. Habe es selbst bei Fusa erlebt, aber die Hoffnung stirbt bekanntlich zuletzt!